Jump to content

Donafenib

From Wikipedia, the free encyclopedia

Donafenib
Clinical data
Trade namesZepsun
Other namesCM-4307
Legal status
Legal status
  • Rx in China
Identifiers
  • 4-[4-[[4-Chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-(trideuteriomethyl)pyridine-2-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H16ClD3F3N4O3
Molar mass470.87 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])NC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
  • InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)/i1D3
  • Key:MLDQJTXFUGDVEO-FIBGUPNXSA-N

Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.

In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment.[1][2]

Donafenib is a kinase inhibitor that targets Raf kinase and various receptor tyrosine kinases.[3] It is a deuterated derivative of sorafenib with improved pharmacokinetic properties.[4][5]

References

[edit]
  1. ^ Keam SJ, Duggan S (November 2021). "Donafenib: First Approval". Drugs. 81 (16): 1915–1920. doi:10.1007/s40265-021-01603-0. PMID 34591285.
  2. ^ Chen R, Ielasi L, di Carlo A, Tovoli F (February 2023). "Donafenib in hepatocellular carcinoma". Drugs of Today. 59 (2): 83–90. doi:10.1358/dot.2023.59.2.3507751. PMID 36811408.
  3. ^ "Donafenib". NCI Cancer Dictionary. National Cancer Institute, National Institutes of Health.
  4. ^ Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. (September 2021). "Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial". Journal of Clinical Oncology. 39 (27): 3002–3011. doi:10.1200/JCO.21.00163. PMC 8445562. PMID 34185551.
  5. ^ Qin S, Bi F, Xu J, Du C, Fan Q, Zhang L, et al. (2020). "P-86 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial". Annals of Oncology. 31: S117 – S118. doi:10.1016/j.annonc.2020.04.168.
Devtools
Installation completed

Devtools is now enabled.

While getting ready, it missed the HTTP request for this page and related assets. Do you want to reload the page to start again?